Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
COVID-19
About this trial
This is an interventional prevention trial for COVID-19 focused on measuring SARS-CoV-2, effectiveness, hybrid immunity, booster immunization, adaptive platform trial
Eligibility Criteria
Inclusion Criteria: Adults aged 18 years and over, including the elderly over 60 years and those with underlying diseases. Volunteers are able and willing to comply with the requirements of the clinical trial protocol and sign the informed consent form. ≥ 4 months from the last SARS-CoV-2 infection (or never been infected), and 6 months or more from the first booster immunization of the COVID-19 vaccine. Exclusion Criteria: Volunteers have suspected symptoms of COVID-19 when enrolled, such as dry throat, sore throat, cough, etc. The COVID-19 Antigen Quick Test Kit is positive when volunteers are enrolled. Fever, temperature > 37.0°C. Have received a second COVID-19 vaccine booster immunization. Have a history of serious adverse reactions related to the vaccine and/or have a history of severe allergic reactions to any component of the investigational vaccine (only applicable to the vaccine groups). Pregnant or lactating women. HIV infection, tuberculosis, low immunity caused by disease or long-term medication. Acute disease or acute onset of chronic disease. Epilepsy and other progressive neurological disorders. Other situations that are not suitable for participating in this research, according to the judgment of the researcher.
Sites / Locations
- Jiangsu Provincial Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
No Intervention
Group 1
Group 2
Group 3
Group 4
Group 5
Subjects are assigned to receive one dose of intramuscularly administered Ad5-nCoV vaccine as the second booster.
Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster.
Subjects are assigned to receive two doses of DelNS1-2019-nCoV-RBD-OPT1 vaccine as the second booster.
Subjects are assigned to receive one dose of SYS6006 vaccine as the second booster.
Subjects are not assigned any vaccines served as a blank control.